In the News

30. October 2020

Practical test for new TIVITA® Camera

The first two prototypes of our new TIVITA Camera have been undergoing practical testing for four weeks in two clinics, with which we have been working closely and fruitfully for years. The goal is to evaluate and finally optimize the usability for the finished product, so that future customers will receive a device that they like to use to support their daily work. It goes without saying that in the current phase the camera is not being used on patients but on resectates in order to simulate a real clinical application.

We are looking forward to the upcoming feedback to make the TIVITA Camera even better for you!

25. September 2020

First clinical study comparing hyperspectral imaging technique with ICG fluorescence angiography

Recently, for the first time, a comparative study on hyperspectral imaging (TIVITA® Tissue) and fluorescence angiography (indocyanine green) for the determination of the cutting edge in colorectal resections was published in the International Journal of Colorectal Disease by the team of Prof. Ines Gockel and PD Dr. Boris Jansen-Winkeln. This prospective, human study showed that both methods visualize blood perfusion comparably well and safely, so that with their support well perfused anastomoses can be created.
We are very pleased with this publication and the positive results, which once again emphasize the clinical relevance and performance of hyperspectral imaging.

23. September 2020

Publication in Annals of Surgery

With the publication “Hyperspectral Imaging (HSI) of Human Kidney Allografts” by Robert Sucher et al. the team succeeded in addressing one of the best journals in surgery and laid the foundation for hopefully many more projects.

The topic of transplantation medicine has only been with us for a short time, but will become increasingly important in the future. At present, physicians lack measurement techniques that allow for an objective intraoperative assessment of the viability and performance of transplants. Since at present only the TIVITA® is available as a measuring device for such applications, we are very pleased about this publication.

We would like to thank the team around PD Dr. Robert Sucher on behalf of the entire company for their confidence in the HSI technology, the time invested and the great work on our TIVITA®.

Hyperspectral imaging in wound medicine: A systematic review

Diaspective Vision GmbH was founded with the aim of objectifying and thus improving wound medicine. Today, after 5 years on the market, there is a growing awareness in medicine that there must be technologies that allow better, more objective diagnostics, so that positive results can be achieved more quickly in the treatment of (chronic) wounds.

Our product TIVITA® is already represented in many other medical applications, which are generally considered to be more important. Nevertheless, the topic of wound medicine is permanently present for us. For this reason, we are pleased that recently, for the first time, a review article on hyperspectral imaging in wound medicine was published in which TIVITA® is represented.

SAIKO, Gennadi, et al. Hyperspectral imaging in wound care: A systematic review. International Wound Journal, 2020.

Research project HyperLimit-CAM approved

At the beginning of 2019 we already met with doctors from Rostock and Greifswald to discuss a potential project on amputation levels and parathyroid recognition. It quickly became clear that this is a promising concept. For this reason, a project was submitted to the Technologie-Beratungs-Institut in Mecklenburg-Vorpommern together with the University Medical Center Greifswald, the Südstadtklinikum Rostock and the University of Applied Sciences Wismar. Now, about one and a half years later, the first kick-off meeting for the official start of the project took place.

The project is divided into two parts:
In the first part, the amputation height in lower extremity surgery is to be assessed in order to minimize the error rate in these same surgeries. The goal is to reduce the error rate by 50% by using hyperspectral imaging.

The second part of the project deals with the recognition of the parathyroid glands. The removal of these glands often leads to complications due to insufficient recognition. This is to be avoided by combining hyperspectral and fluorescence imaging.

Many thanks to the TBI for the possibility to realize this project. We are looking forward to the upcoming tasks and hope to further improve the clinical outcome for patients with the results of this project.

This project is co-financed by the European Union through the European Regional Development Fund.

25. August 2020

(Deutsch) TIVITA® bei Instagram

Sorry, this entry is only available in German.

>> view all news(71)